Although we acknowledge that most of the studies included in our meta‐analyses were single‐arm/open‐label trials and the limitations of cross‐trial comparisons, the pooled response rates observed in our study suggest that FLT3 inhibitors are quite effective in the treatment of patients with R/R AML who are likely predicted to be chemo‐refractory. This evidence concerns the gene FLT3 and acute myeloid leukemia.